The year 2020 was a great year for psychedelics; more than two dozen companies focusing on psychedelics in some manner became publicly listed. That success certainly seems to have sparked interest in what the sector will see in 2021. A recent Benzinga article, titled “What Will the Psychedelics Space Look Like in 2021? Experts Weigh In” noted that as psychedelics grow closer to receiving federal legalization, scientific, regulatory and corporate developments are almost daily news. Experts in the field are looking for new clinical and R&D initiatives to emerge, investment opportunities to increase, and public acceptance to expand. In addition, equity analysts and financial media may accept — and even declare — psychedelics as a new biotech asset class and industry. The article named several up-and-coming companies in the space, including Canopy Growth (NYSE: CGC), MindMed (NEO: MMED) (OTCQB: MMEDF), Red Light Holland (CSE: TRIP), Numinus (TSX.V: NUMI), Novamind (CSE: NOVA), NeonMind Biosciences (CSE: NEON), Horizons ETFs Management, Field Trip (CSE: FTRP) (OTC: FTRPF), and CaaMTech. “By the end of 2021, I expect the conversation about access to therapeutic outcomes using what were previously known as psychedelics to be a global conversation,” said former CEO and founder of Canopy Growth (NYSE: CGC) Bruce Linton in the article. “This conversation has got more points of active discussion occurring right now than the cannabis one had for the first five years . . . . [2021 will bring] an abrupt start to a real conversation [around psychedelic medicine].”
To read the full article, visit https://ibn.fm/2yPnt
Benzinga is a media and data technology company created by founder Jason Raznick to empower a new generation of investors. Raznick launched Benzinga.com in 2010, and it has since grown to become a hub for actionable information on the capital markets with approximately 2 million readers a month. Benzinga.com is supported by a high-speed newswire, Benzinga Pro, which is home to exclusive market-moving news. For more information about Benzinga, please visit www.Benzinga.com.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.